首页> 美国政府科技报告 >B III Tubulin Disulfide Bonds and Drug Resistance: A Novel Approach to the Treatment of Breast Cancer
【24h】

B III Tubulin Disulfide Bonds and Drug Resistance: A Novel Approach to the Treatment of Breast Cancer

机译:B III微管蛋白二硫键和耐药性:一种治疗乳腺癌的新方法

获取原文

摘要

Tubulin, a potential target for chemotherapy, plays an important role in different cellular functions including mitosis and cell division. Tubulin consists of mainly alpha and beta subunits: each subunit exists in several isoforms. The distribution and expression of beta- isoforms differ from tissue to tissue: beta-II and beta-IV are ubiquitously expressed while beta-III expression is restricted to neurons and cancer cells. Moreover, alpha-beta-III has least affinity for anti-tubulin drugs compared to alpha-beta-II and alpha- beta-III tubulin. In this study, we correlated the expression of beta-III tubulin and oxidative stress related to drug resistance in cancer cells. We have established a taxol-resistant BT474 breast cancer cell line (IC50=0.97 nM) from the taxol-sensitive line of BT454 (1C50=0.5 nM). We found that taxol-resistant BT454 cell line experienced higher oxidative stress compared to its sensitive line and the expression of beta-III tubulin was also found significantly elevated in drug-resistant cells. However, the expression of actin and beta-II tubulin remained unchanged. These data therefore, strongly suggest that selective elevation of expression of specific beta-III-tubulin cause development of drug resistance in breast cancer cells and the elevated level of formation of reactive oxygen species might be directly related to drug resistance.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号